To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Methylene Blue for the Treatment of Lumbar Facet Joint Syndrome

Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
February 2022

Methylene Blue for the Treatment of Lumbar Facet Joint Syndrome

Vol: 198| Issue: 1| Number:1| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Clinical Effects and Safety of the Use of Methylene Blue for the Treatment of Lumbar Facet Joint Syndrome.

Pain Physician. 2022 Jan;25(1): E15-E26.

Contributing Authors:
X Yu J Zhang M Wang Y Yang W Zhang D Su L Liao H Yang H Fang X Wang

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

One hundred and twenty patients with lumbar facet joint syndrome due to osteoarthritis were randomized to receive an ultrasound-guided intra-articular injection of methylene blue (n=60) or diprospan (n=60). The primary outcome of interest was pain on a Numeric Rating Scale (NRS), measured up to 6 months post-operation. Secondary outcomes of interest included lumbar function, sleep quality, depress...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.